The jury has spoken in the latest Actos trial, and the verdict was this: Takeda Pharmaceutical didn't properly flag the risks of its diabetes drug, and Takeda should pay $1.7 million to the family of Diep An, an Actos patient who died of bladder cancer.
To improve the delivery of intravenous drugs, researchers have developed a computerized system that not only determines the exact dosage but also identifies the contents of a fluid in the IV line in real time.
Which doctors to flag for reckless OxyContin prescribing may soon be a decision that's out of maker Purdue Pharma's hands, at least in California. Thursday, a spokesman from Purdue Pharma confirmed that the company had turned over a list of 49 California doctors it suspected of risky script-writing to the Medical Board of California.
California is pushing some new legislation that drugmakers and physicians were none too happy with in its original form. But after some amendments, a slate of reforms to increase authorities' powers to crack down on risky narcotics prescribers has made its way to the desk of Gov. Jerry Brown. The three bills now await his signature to make them law.
Delcath Systems failed to impress the FDA with its cancer drug delivery system Melblez, as the U.S. authority asked the company in a complete response letter for further trials before the chemotherapy device can move forward.
The FDA, under pressure to help curb abuse of opioid painkillers, has taken yet another step to dampen their use. The agency said today that it is "invoking its authority" to require that long-acting and extended release drugs should only be used for severe pain and only when other measures don't work.
German regulators have responded to Der Spiegel 's questions about Xarelto side effects. Answer? The Federal Institute for Drugs and Medical Devices sees no new red flags for patients using the clot-fighting drug developed by Bayer and Johnson & Johnson.
The number of side-effect reports on Bayer's anticoagulant drug Xarelto appears to be increasing, and some doctors are growing wary of using the drug as a standard first-line treatment, the German newspaper Der Speigel reports.
A third compounding pharmacy is recalling sterile injectable drugs nationwide because it can't rely on the results of an outside laboratory that tested them for sterility. The recall comes as the FDA is applying more heat to this niche of the drugmaking market despite the lack of its clear authority to do so.
For the second time, Takeda Pharmaceuticals is trying to fend off claims that it didn't warn Actos patients about the diabetes drug's links to bladder cancer.